Track topics on Twitter Track topics that are important to you
SANTA CLARA, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2019.
“Our third quarter performance was marked by many key accomplishments as our team continues to deliver solid, balanced, results across our domestic and international businesses,” said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. “Additionally, we have achieved several important operational successes, including doubling the number of patients enrolled in CAD III since last quarter, initiating our CAD IV study in Japan and completing the full launch of our S4 device to safely address the large number of patients who suffer from below the knee peripheral disease. We look forward to building on this progress as we continue our efforts to positively impact patient outcomes worldwide.”
Third Quarter 2019 Financial Results
Revenue for the third quarter of 2019 was $11.3 million, an increase of $7.7 million, or 215%, compared to the third quarter of 2018. The growth was primarily driven by the expansion of the U.S. salesforce and international distributor network.
Gross profit for the third quarter of 2019 was $6.9 million compared to $1.6 million for the third quarter of 2018. The gross margin percentage for the third quarter of 2019 increased to 61% compared to 45% in the third quarter of 2018, driven primarily by continued improvements in production processes and greater absorption of fixed costs by higher production.
Operating expenses were $20 million for the third quarter of 2019 compared to $11.7 million in the corresponding prior year period, an increase of 71%, primarily driven by salesforce expansion and higher clinical costs from the CAD III IDE and CAD IV Japan studies.
Net loss was $13 million in the third quarter of 2019, as compared to $10.2 million in the corresponding period of the prior year. Net loss per share was $0.46 in the third quarter of 2019.
Cash, cash equivalents and short-term investments totaled $114.1 million as of September 30, 2019.
2019 Financial Guidance
Shockwave Medical projects revenue for the full year 2019 to range from $41 million to $42 million, which would represent 234% to 242% growth over the company’s prior year revenue.
Shockwave Medical will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on Thursday, November 7, 2019 to discuss its third quarter 2019 financial results. The call may be accessed through an operator by calling (866) 795-9106 for domestic callers and (470) 495-9173 for international callers using conference ID number 1427729. A live and archived webcast of the event will be available at https://ir.shockwavemedical.com/.
About Shockwave Medical, Inc.
Shockwave Medical is focused on developing and commercializing products intended to transform the treatment of calcified vascular disease by establishing a new standard of care with Intravascular Lithotripsy (IVL). IVL seeks to minimize trauma within the artery by delivering pulsatile sonic pressure waves locally to fracture both intimal and medial calcium in the artery wall, but pass through surrounding soft vascular tissue in a safe manner. To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com.
This press release contains statements relating to Shockwave’s expectations, projections, beliefs, and prospects (including statements regarding Shockwave’s financial and business outlook), which are “forward-looking statements” within the meaning of the federal securities laws and by their nature are uncertain. Words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plans,” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to achieve or sustain profitability; failure to effectively market existing products; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; the inability to attain coverage and adequate reimbursement for procedures using our products; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission (SEC), including under the section entitled “Risk Factors” in our prospectus dated March 6, 2019. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
Debbie Kaster, Gilmartin Group
|SHOCKWAVE MEDICAL, INC.|
|Balance Sheet Data|
|September 30, |
|December 31, |
|Cash and cash equivalents||$||39,452||$||39,643|
|Accounts receivable, net||5,551||2,850|
|Prepaid expenses and other current assets||2,199||1,112|
|Total current assets||131,075||48,736|
|Operating lease right-of-use assets||2,155||—|
|Property and equipment, net||4,111||2,619|
|LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ |
|Term notes, current portion||6,667||1,667|
|Lease liability, current portion||742||—|
|Total current liabilities||19,391||9,371|
|Lease liability, noncurrent||1,543||—|
|Term notes, noncurrent portion||8,705||13,383|
|Convertible preferred stock warrant liability||—||313|
|Convertible preferred stock||—||152,806|
|STOCKHOLDERS’ EQUITY (DEFICIT):|
|Additional paid-in capital||271,394||4,275|
|Accumulated other comprehensive loss||57||—|
|TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)||108,250||(122,588||)|
|TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND |
STOCKHOLDERS’ EQUITY (DEFICIT)
|SHOCKWAVE MEDICAL, INC.|
|Statement of Operations Data|
|(in thousands, except share and per share data)|
|Three Months Ended |
|Nine Months Ended |
|Cost of product revenue||4,401||1,973||11,606||3,946|
|Research and development||8,368||5,533||22,778||16,579|
|Sales and marketing||8,192||4,801||21,023||12,611|
|General and administrative||3,437||1,369||9,684||4,137|
|Total operating expenses||24,398||13,676||65,091||37,273|
|Loss from operations||(13,065||)||(10,076||)||(36,476||)||(30,072||)|
|Change in fair value of warrant liability||—||(104||)||(609||)||(53||)|
|Other income, net||385||166||1,518||489|
|Net loss before taxes||(12,931||)||(10,172||)||(36,313||)||(29,852||)|
|Income tax provision||26||6||51||27|
|Net loss per share, basic and diluted||$||(0.46||)||$||(5.73||)||$||(1.66||)||$||(17.15||)|
|Shares used in computing net loss per share, basic and diluted||28,085,821||1,776,249||21,886,396||1,742,572|
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...